Histone deacetylases (HDACs) are considered to be among the most promising targets in
drug development for cancer therapy, and first-generation histone deacetylase inhibitors …

This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors
(HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …

Abnormal epigenetic control is a common early event in tumour progression, and aberrant
acetylation in particular has been implicated in tumourigenesis. One of the most promising …

Epigenetic treatment has been approved by regulatory agencies for haematological
malignancies. The success observed in cutaneous lymphomas represents a proof of …

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

Among many anticancer drugs collectively named “targeted or molecular therapies”
epigenetic drugs are clearly promising. Differently from other agents targeting a single gene …

Cervical cancer remains one of the greatest killers of women worldwide. It is difficult to
foresee a dramatic increase in cure rate even with the most optimal combination of cytotoxic …

Background: Epigenetic aberrations lead to chemotherapy resistance; hence, their reversal
by inhibitors of DNA methylation and histone deacetylases may overcome it. Patients and …

The histone deacetylase inhibitors (HDACi) are a group of small molecules that target
histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use …

For a number of patients with bipolar disorder, current pharmacotherapy is generally
insufficient. Despite adequate treatment, patients continue to have recurrent mood episodes …